February 2024: In its public comment, NCHR supported EPA’s proposed lead and copper rule improvements (LCRI) and suggested strengthening safeguards such as lowering the action lead level to 5 ppb or less, more attention to schools, daycares, and afterschool facilities, better enforcement, and not replacing lead pipes with PVC or other dangerous pipes.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Coalition follow-up letter to FDA regarding FDA overruling their own scientists
February 5, 2024: The Patient, Consumer, and Public Health Coalition expressed their strong concerns when the Food and Drug Administration (FDA) Center Directors publicly undermine or privately overrule the recommendations of their own scientists’ and statisticians’ regarding applications for accelerated approval and full approval.
Read More »Coalition follow-up letter to FDA regarding FDA overruling their own scientists
February 5, 2024: The Patient, Consumer, and Public Health Coalition expressed their strong concerns when the Food and Drug Administration (FDA) Center Directors publicly undermine or privately overrule the recommendations of their own scientists’ and statisticians’ regarding applications for accelerated approval and full approval.
Read More »NCHR Provides Recommendations for the Public Meeting Agenda to Reduce Added Sugar Consumption in the United States
January 22, 2024: NCHR recommends that FDA policies are discussed as a key strategy to reduce added sugar consumption at the national public meeting on hunger. The FDA should require targets for added sugar amounts in packaged food, hold restaurants accountable for disclosing added sugar content, and regulate food with artificial sweeteners.
Read More »NCHR Comments on USPSTF Draft Recommendations on Interventions for Adolescents with a High Body Mass Index
January 16, 2024: NCHR strongly supports USPSTF’s draft recommendation on using behavioral interventions to manage unhealthy weight gain in adolescents over six years of age with a body mass index at the 95th percentile for their age and sex. More research is needed to clearly show the safety and efficacy of weight loss medications in this patient population.
Read More »